Opinion: ‘They all think I’m insane’: What it’s like to start medical residency at 72

Every time Dawn Zuidgeest-Craft intended to apply to medical school, life got in the way. But after 45 years as a neonatal nurse practitioner, she finally did it, beginning medical school at the age of 69 in 2022.

The pivotal moment came after her husband had a health scare. As she told me on this episode of the “First Opinion Podcast,” she sat him down and said, “‘Well, honey, you know, this is crazy. You literally almost died. And life is too dang short. What’s on your bucket list?’ And he said, ‘I really want to travel the world.’ And I said, ‘Well, I still want to go to med school.’”

Read the rest…

Are Republicans turning against medications for treating opioid addiction?

When Robert F. Kennedy Jr. took office in February 2025, he broke new ground as the first health secretary openly in recovery from addiction to drugs and alcohol. 

At a public appearance soon after, he delivered precisely the message that many substance use experts had hoped to hear: that evidence-based medications for treating opioid addiction, in particular, would remain essential components of the country’s response to its drug overdose crisis. 

Read the rest…

STAT+: As the U.S. looks on, European countries feel growing pressure on drug prices

LONDON — In Europe, two divergent paths are emerging as countries grapple with what to do about drug prices, affecting pharma companies and patients across the continent — and testing the influence of the U.S.

In the U.K., after a pressure campaign from both pharma companies and the Trump administration, the government has adopted more industry-friendly policies while also simply promising to spend more on medicines.

Germany, another of the continent’s biggest markets, is headed in the opposite direction. Facing growing deficits in its health budget, the government has proposed moves that would cut spending and increase the fees the industry has to pay.

Continue to STAT+ to read the full story…

[Articles] Complement C3 inhibition restores myasthenia gravis AChR antibody-mediated muscle pathophysiology

These findings indicate that targeting the α-subunit impairs nAChR-dependent calcium signaling and can induce complement activation. Disrupted signaling and reduced nAChR levels were effectively restored by C3 inhibition, which blocks multiple downstream pathways; thus, terminal complement activation leading to MAC formation is a suggested, but it may not be the only mechanism. Overall, the results highlight C3 as a promising upstream therapeutic target and support combining subunit-specific interventions with proximal complement blockade in MG.

T-Cell Synapse Formation Is Restrained by PTPN22–PSTPIP1 Signaling

T cells don’t simply switch on—they reshape themselves. When these immune sentinels recognize a target, they rapidly reorganize their internal scaffolding to build an immunological synapse, a nanoscale interface that determines how strongly they respond. But that architectural overhaul needs brakes. Without them, T cells risk becoming hypersensitive, reacting to weak cues, and drifting toward autoimmunity. Now, new work reveals that one of those brakes—PTPN22 (proline-serine-threonine phosphatase–interacting protein 1)—acts not only on signaling molecules but also on the cytoskeletal machinery that sculpts the synapse itself.

In a study published in Science Signaling, lead author Megan Joseph, PhD, of University College London and colleagues uncover how PTPN22 interacts with the cytoskeletal adaptor protein PSTPIP1 to restrain actin remodeling at the T‑cell synapse. Their paper, “PTPN22 regulates T-cell synapse formation through PSTPIP1-dependent actin remodeling,” shows that this phosphatase plays a previously unappreciated role at the plasma membrane, shaping how T cells respond to antigens of varying affinity. As the authors wrote, “These findings uncover a PTPN22–PSTPIP1 signaling axis that is critical for regulating cytoskeletal remodeling and receptor organization, providing insights into T-cell hyperactivation that may be relevant to autoimmune disease.”

PTPN22 is already well known as a negative regulator of early T‑cell activation. Variants in the gene, including the autoimmune‑associated R620W allele, have been linked to diseases ranging from lupus to rheumatoid arthritis. Using super‑resolution DNA‑PAINT imaging, Joseph et al. visualized how T cells reorganize their actin networks as they engage activating ligands. In wild‑type Jurkat cells, PTPN22 helped maintain orderly actin dynamics. In its absence, however, PSTPIP1 accumulated at T cell receptors (TCRs), disrupting Arp2/3‑dependent actin polymerization and generating dense central F‑actin foci, as well as enhanced Ca2+ signaling, especially under low-affinity stimulation of the TCR, according to the paper.

This hyper‑remodeling had functional consequences. PTPN22‑deficient cells became unusually sensitive to low‑affinity antigens, responding more vigorously than their wild‑type counterparts. “Autoimmunity is inherently linked to immune tolerance mechanisms normally associated with low-affinity TCR responses to self, which, when breeched lead to inappropriate immune reactions. To better understand how PTPN22 contributes to these processes, we used WT and PTPN22 KO TCR−/− Jurkat cells engineered to express a transgenic TCR with high affinity for the pTax peptide and low affinity for the pHuD peptide,” the authors wrote.

Joseph and colleagues suggest that understanding this axis could inform both autoimmune research and efforts to modulate T‑cell activation in cancer immunotherapy. By mapping how PTPN22 and PSTPIP1 coordinate actin remodeling, the study provides a mechanistic foothold for exploring how synapse architecture shapes immune outcomes.

The post T-Cell Synapse Formation Is Restrained by PTPN22–PSTPIP1 Signaling appeared first on GEN – Genetic Engineering and Biotechnology News.